Skip to main content
ARS Home » Northeast Area » Boston, Massachusetts » Jean Mayer Human Nutrition Research Center On Aging » Research » Publications at this Location » Publication #397483
Research Project: Nutrition, Sarcopenia, Physical Function, and Skeletal Muscle Capacity During Aging

Location: Jean Mayer Human Nutrition Research Center On Aging

Title: Challenges in the development of drugs for sarcopenia and frailty - report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force

Author
item CESARI, MATTEO - University Of Milan
item BERNABEI, R. - Agostino Gemelli University Hospital Foundation Irccs
item VELLAS, BRUNO - University Of Toulouse
item FIELDING, ROGER - Jean Mayer Human Nutrition Research Center On Aging At Tufts University
item ROOKS, D. - Novartis Institutes
item AZZOLINO, D. - University Of Milan
item MARIANI, J. - Pierre And Marie Curie University
item OLIVA, A.A. - Longeveron
item BASHIN, S. - Brigham & Women'S Hospital
item ROLLAND, Y. - University Of Toulouse

Submitted to: The Journal of Frailty and Aging
Publication Type: Proceedings
Publication Acceptance Date: 3/13/2022
Publication Date: 4/1/2022
Citation: Cesari, M., Bernabei, R., Vellas, B., Fielding, R.A., Rooks, D., Azzolino, D., Mariani, J., Oliva, A., Bashin, S., Rolland, Y. 2022. Challenges in the development of drugs for sarcopenia and frailty - report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force. The Journal of Frailty and Aging. 11:135-142. https://doi.org/10.14283/jfa.2022.30.
DOI: https://doi.org/10.14283/jfa.2022.30

Interpretive Summary:

Technical Abstract: Sarcopenia and frailty represent two burdensome conditions, contributing to a broad spectrum of adverse outcomes. The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force met virtually in September 2021 to discuss the challenges in the development of drugs for sarcopenia and frailty. Lifestyle interventions are the current mainstay of treatment options in the prevention and management of both conditions. However, pharmacological agents are needed for people who do not respond to lifestyle modifications, for those who are unable to adhere, or for whom such interventions are inaccessible/unfeasible. Preliminary results of ongoing trials were presented and discussed. Several pharmacological candidates are currently under clinical evaluation with promising early results, but none have been approved for either frailty or sarcopenia. The COVID-19 pandemic has reshaped how clinical trials are conducted, in particular by enhancing the usefulness of remote technologies and assessments/interventions.